ArticleFrontiers in pharmacology2025
Qingfei Dayuan granules and decoction alleviate acute lung injury via TLR4 signaling pathway modulation, gut microbiota regulation, and metabolic reprogramming.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore and compare the therapeutic effects and underlying mechanisms of Qingfei Dayuan Granules (QFDYGs) and Qingfei Dayuan Decoctions (QFDYDs) for the treatment of acute lung injury (ALI), focusing on the modulation of the TLR4 signaling pathway, intestinal microbiota, and related metabolic pathways. Methods: The active metabolite contents were measured by ultrahigh-performance liquid chromatography. A mouse model of lipopolysaccharide-induced ALI (tracheal instillation) was used to assess efficacy. After drug administration, lung tissue damage was analyzed by hematoxylin-eosin staining and quantification of inflammatory cytokines and oxidative stress biomarkers with enzyme-linked immunosorbent assays. Components of the TLR4 signaling pathway were quantified by Western blot analysis. Intestinal flora regulation was assessed by 16S rRNA sequencing with metabolic pathway analysis via metabolomics. Multivariate statistical methods were applied to analyze differences in gut microbiota and metabolites between groups. Results: Levels of eight metabolites were 2.44-3.74 times greater following treatment with QFDYGs vs. QFDYDs, although both demonstrated significant protective effects against pulmonary inflammation through TLR4 signaling pathway modulation, gut microbiota restoration, and metabolic regulation. QFDYDs more effectively suppressed production of the pro-inflammatory cytokines TNF-α and IL-1β, while QFDYGs exhibited superior capability to reduce malondialdehyde levels and restore glutathione, catalase, and superoxide dismutase activities. QFDYGs demonstrated greater inhibition of the TLR4-TRIF/MyD88-NF-κB-NLRP3 signaling pathway, whereas QFDYDs more effectively normalized lung injury-induced metabolic changes. Both formulations significantly modulated metabolic pathways, as evidenced by sustained changes to 11 key metabolites, and improved intestinal microbiota composition and functionality. Conclusion: Both QFDYGs and QFDYDs offer protection against ALI. QFDYGs could serve as effective alternatives to QFDYDs, with equivalent or potentially superior therapeutic effects. The choice between QFDYGs and QFDYDs should be guided by specific clinical presentations and therapeutic goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.